PubRank

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Clinical Trial ID NCT01272037

PubWeight™ 39.31‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01272037

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2011 8.24
2 Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol 2014 2.73
3 Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2011 2.38
4 Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 2013 2.12
5 The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013 1.71
6 Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 2012 1.42
7 The 21-gene recurrence score and locoregional recurrence in breast cancer patients. Ann Surg Oncol 2014 1.40
8 Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol 2013 1.16
9 Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials 2012 1.10
10 uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res 2014 1.02
11 The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemp Clin Trials 2012 0.97
12 Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res 2015 0.93
13 Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med 2015 0.93
14 The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients. Breast Cancer Res Treat 2013 0.91
15 Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score. Int J Mol Sci 2013 0.86
16 Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl) 2011 0.83
17 Breast cancer: Chemotherapy and the recurrence score-results as expected? Nat Rev Clin Oncol 2015 0.83
18 Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age. Adv Ther 2015 0.83
19 Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer? Genet Med 2015 0.81
20 Current approaches for neoadjuvant chemotherapy in breast cancer. Eur J Pharmacol 2013 0.80
21 Outcomes and prognostic factors in modern era management of major salivary gland cancer. Oral Oncol 2015 0.79
22 Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years. J Natl Compr Canc Netw 2015 0.78
23 Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer. Am J Clin Oncol 2014 0.78
24 A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. Breast Cancer Res Treat 2013 0.78
25 Breast Cancer Biomarkers: Utility in Clinical Practice. Curr Breast Cancer Rep 2013 0.78
26 Reply to E.J. Moylan et al. J Clin Oncol 2014 0.75
27 Patterns in target-directed breast cancer research. Springerplus 2016 0.75
28 Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes. Breast Cancer (Dove Med Press) 2015 0.75
29 A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer. Pharmaceuticals (Basel) 2015 0.75
30 Should Sentinel Lymph Node Biopsy for Patients with Early Breast Cancer Be Abandoned? Not So Fast. Clin Med Insights Oncol 2016 0.75
31 Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. EJC Suppl 2013 0.75
Next 100